Friday 6-6-2014 Celldex Therapeutics Inc (CLDX) $C
Post# of 98
Posted On: 06/08/2014 9:57:59 PM
Friday 6-6-2014 Celldex Therapeutics Inc (CLDX) $CLDX opened at 15.13 hitting the high price of 15.20 and a day low of 14.52 with a total volume of 1,773,400. CLDX had a previous close of 15.15 and has been seeing an average volume of 2,881,150.
Overall Average: 0% Hold
Recent stock forum discussions about CLDX http://investorshangout.com/search?q=CLDX&...mp;yt0=Go!
Swing Trade Ideas for Friday, June 6: Celldex, Two Others
at The Street - Fri Jun 06, 9:06AM CDT
Celldex broke out yesterday. Does it more room to run? Plus, two other stocks to consider. (full story)
Celldex Therapeutics (CLDX) Soars: Stock Adds 12.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 8:39AM CDT
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose nearly 13% on the day. (full story)
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
M2 - Thu Jun 05, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jll46/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering. During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Scope - A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis - In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target - Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate - Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in GBM Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed drugs - Temodar (temozolomide) - Merck - Avastin (bevacizumab) - Roche - BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan) - BiCNU (carmustine) - Bristol-Myers Squibb - Gliadel Wafer (carmustine in polifeprosan) - Eisai - Lomustine - Carboplatin - Cyclophosphamide - Etoposide - Irinotecan 4 Glioblastoma Pipeline - DCVax-L - Northwest Biotherapeutics - Rindopepimut (CDX-110) - Celldex Therapeutics - Avastin (bevacizumab)- Roche - ICT-107 - ImmunoCellular Therapeutics - Cotara- Peregrine Pharmaceuticals - Eir-060- EirGen Pharma - Heat Map of Safety and Efficacy and Competitor Matrix for Glioblastoma Multiforme Pipeline 5 Market forecasts 6 Deals and Strategic Consolidations - Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical - Immatics Biotechnologies Enters into Agreement with Cancer Research UK - ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania - Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children's Hospital Medical Center - Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center 7 Appendix For more information visit http://www.researchandmarkets.com/research/4j...ioblastoma (full story)
'Mad Money' Lightning Round: Devon Energy Goes to $90
at The Street - Wed Jun 04, 5:00AM CDT
Cramer is no fan of Nu Skin Enterprices but thinks Alcoa is good. (full story)
Jim Cramer's 'Mad Money' Recap: Embrace the Powerful Trends
at The Street - Tue Jun 03, 7:19PM CDT
You can learn a lot by listening to the footsteps of the thundering herd, Cramer says. (full story)
Celldex Therapeutics' Varlilumab Continues to Demonstrate Very Favorable Profile
GlobeNewswire - Mon Jun 02, 1:12PM CDT
--Very well tolerated with notable immunologic and anti-tumor activity in Phase 1 Study; Will enter multiple combination studies in 2H 2014-- (full story)
Oncothyreon Collaborates with Celldex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 30, 3:40PM CDT
Oncothyreon Inc. (ONTY) announced that it has entered into a collaboration agreement with Celldex Therapeutics, Inc., (CLDX). (full story)
'Fast Money' Recap: What's On? How About Netflix Stock?
at The Street - Fri May 30, 4:00AM CDT
The trading panel discussed Netflix's valuation and whether shares are worth buying. (full story)
Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab
PR Newswire - Thu May 29, 7:00AM CDT
Oncothyreon Inc. (NASDAQ: ONTY) and Celldex Therapeutics, Inc., (NASDAQ: CLDX) today announced that they have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. (full story)
Bristol-Myers & CytomX Therapeutics Join Forces - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 10:50AM CDT
Bristol-Myers (BMY) inked an immuno-oncology deal with CytomX. (full story)
Celldex Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Wed May 28, 10:10AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Jefferies 2014 Global Healthcare Conference on June 4, 2014 at 10:30 a.m. ET at the Grand Hyatt in New York City. (full story)
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review 2014
M2 - Wed May 28, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hgsknm/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Johnson & Johnson - Boehringer Ingelheim GmbH - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Genentech, Inc. - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Plexxikon Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astex Pharmaceuticals, Inc. - Santaris Pharma A/S - A. Menarini Industrie Farmaceutiche Riunite Srl - Bayer AG - Harbor Therapeutics, Inc. - Celldex Therapeutics, Inc. - Oncogenex Pharmaceuticals, Inc. - AnGes MG, Inc. - e-Therapeutics plc - Hybrigenics S.A. - Fujifilm Corporation - CureVac GmbH - Tokai Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - CureTech Ltd. - Viamet Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/hgsknm/hormone (full story)
Top Gainers Roundup -- Research on Horizon Pharma, Celldex Therapeutics, Extreme Networks, and WidePoint
PR Newswire - Wed May 28, 5:17AM CDT
The US markets saw a positive sentiment on Tuesday, May 27, 2014, with the NASDAQ Composite closing at 4,237.07, up 1.22%, the Dow Jones Industrial Average ending the session at 16,675.50, up 0.42% and the S&P 500 finishing 0.60% higher at 1,911.91. The gains were broad based as nine out of ten sectors finished on a higher note. A number of stocks saw large movements, including Horizon Pharma Inc. (NASDAQ: HZNP), Celldex Therapeutics Inc. (NASDAQ: CLDX), Extreme Networks Inc. (NASDAQ: EXTR) and WidePoint Corp. (NYSE MKT: WYY). Free technical research on HZNP, CLDX, EXTR and WYY can be downloaded upon signing up at: (full story)
Critical Alerts For Celldex Therapeutics, Best Buy, Weibo, Sarepta Therapeutics, and Dollar Tree Released By InvestorsObserver
PR Newswire - Fri May 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CLDX, BBY, WB, SRPT, and DLTR. (full story)
Shares of CLDX Down 48.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 22, 9:11AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 2 months, Celldex Therapeutics has returned 48.21% as of today's recent price of $12.85. (full story)
Financial Results, Data Presentations, and Breakthrough Therapy Designation - Analyst Notes on Insys, Seattle Genetics, Cubist, Celldex and Clovis
PR Newswire - Thu May 22, 6:10AM CDT
Today, Analysts Review released its analysts' notes regarding Insys Therapeutics, Inc. (NASDAQ: INSY), Seattle Genetics Inc. (NASDAQ: SGEN), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Celldex Therapeutics Inc. (NASDAQ: CLDX) and Clovis Oncology, Inc. (NASDAQ: CLVS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2784-100free. (full story)
Celldex Therapeutics (CLDX) Showing Signs Of A Dead Cat Bounce Today
at The Street - Wed May 21, 9:08AM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate (full story)
Biotech Stock Roundup: Celldex, Incyte Tie Up with Big Pharma for Immuno-Oncology - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 21, 8:22AM CDT
The immuno-oncology field is attracting a lot of interest with a couple of deals being announced last week. (full story)
What Bristol and Celldex's Team-Up Means for Investors
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue May 20, 5:30PM CDT
Bristol Myers-Squibb and Celldex agreed to team up in a phase 1/2 study combining nivolumab (Bristol's PD-1 immuno-oncology candidate) and varlilumab. The study will cover several tumor types, potentially including metastatic melanoma,... (full story)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Celldex Therapeutics Is Down 8.9% (CLDX)
Comtex SmarTrend(R) - Mon May 19, 12:50PM CDT
Two weeks ago on May 1st, 2014 Celldex Therapeutics (NASDAQ:CLDX) reported earnings and analysts, on average, expected a loss of $0.27 on sales of $337.0 thousand. The company actually reported a loss of $0.33 per share on sales of $416.0 thousand, missing EPS estimates by $0.06 and matching revenue estimates. Since the company's report, shares of Celldex Therapeutics have fallen from $14.64 to $13.33, representing a loss of 8.9% in the past 18 days. (full story)
Overall Average: 0% Hold
Recent stock forum discussions about CLDX http://investorshangout.com/search?q=CLDX&...mp;yt0=Go!
Swing Trade Ideas for Friday, June 6: Celldex, Two Others
at The Street - Fri Jun 06, 9:06AM CDT
Celldex broke out yesterday. Does it more room to run? Plus, two other stocks to consider. (full story)
Celldex Therapeutics (CLDX) Soars: Stock Adds 12.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 8:39AM CDT
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose nearly 13% on the day. (full story)
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
M2 - Thu Jun 05, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jll46/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering. During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Scope - A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis - In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target - Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate - Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in GBM Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed drugs - Temodar (temozolomide) - Merck - Avastin (bevacizumab) - Roche - BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan) - BiCNU (carmustine) - Bristol-Myers Squibb - Gliadel Wafer (carmustine in polifeprosan) - Eisai - Lomustine - Carboplatin - Cyclophosphamide - Etoposide - Irinotecan 4 Glioblastoma Pipeline - DCVax-L - Northwest Biotherapeutics - Rindopepimut (CDX-110) - Celldex Therapeutics - Avastin (bevacizumab)- Roche - ICT-107 - ImmunoCellular Therapeutics - Cotara- Peregrine Pharmaceuticals - Eir-060- EirGen Pharma - Heat Map of Safety and Efficacy and Competitor Matrix for Glioblastoma Multiforme Pipeline 5 Market forecasts 6 Deals and Strategic Consolidations - Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical - Immatics Biotechnologies Enters into Agreement with Cancer Research UK - ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania - Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children's Hospital Medical Center - Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center 7 Appendix For more information visit http://www.researchandmarkets.com/research/4j...ioblastoma (full story)
'Mad Money' Lightning Round: Devon Energy Goes to $90
at The Street - Wed Jun 04, 5:00AM CDT
Cramer is no fan of Nu Skin Enterprices but thinks Alcoa is good. (full story)
Jim Cramer's 'Mad Money' Recap: Embrace the Powerful Trends
at The Street - Tue Jun 03, 7:19PM CDT
You can learn a lot by listening to the footsteps of the thundering herd, Cramer says. (full story)
Celldex Therapeutics' Varlilumab Continues to Demonstrate Very Favorable Profile
GlobeNewswire - Mon Jun 02, 1:12PM CDT
--Very well tolerated with notable immunologic and anti-tumor activity in Phase 1 Study; Will enter multiple combination studies in 2H 2014-- (full story)
Oncothyreon Collaborates with Celldex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 30, 3:40PM CDT
Oncothyreon Inc. (ONTY) announced that it has entered into a collaboration agreement with Celldex Therapeutics, Inc., (CLDX). (full story)
'Fast Money' Recap: What's On? How About Netflix Stock?
at The Street - Fri May 30, 4:00AM CDT
The trading panel discussed Netflix's valuation and whether shares are worth buying. (full story)
Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab
PR Newswire - Thu May 29, 7:00AM CDT
Oncothyreon Inc. (NASDAQ: ONTY) and Celldex Therapeutics, Inc., (NASDAQ: CLDX) today announced that they have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. (full story)
Bristol-Myers & CytomX Therapeutics Join Forces - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 10:50AM CDT
Bristol-Myers (BMY) inked an immuno-oncology deal with CytomX. (full story)
Celldex Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Wed May 28, 10:10AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Jefferies 2014 Global Healthcare Conference on June 4, 2014 at 10:30 a.m. ET at the Grand Hyatt in New York City. (full story)
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review 2014
M2 - Wed May 28, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hgsknm/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Johnson & Johnson - Boehringer Ingelheim GmbH - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Genentech, Inc. - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Plexxikon Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astex Pharmaceuticals, Inc. - Santaris Pharma A/S - A. Menarini Industrie Farmaceutiche Riunite Srl - Bayer AG - Harbor Therapeutics, Inc. - Celldex Therapeutics, Inc. - Oncogenex Pharmaceuticals, Inc. - AnGes MG, Inc. - e-Therapeutics plc - Hybrigenics S.A. - Fujifilm Corporation - CureVac GmbH - Tokai Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - CureTech Ltd. - Viamet Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/hgsknm/hormone (full story)
Top Gainers Roundup -- Research on Horizon Pharma, Celldex Therapeutics, Extreme Networks, and WidePoint
PR Newswire - Wed May 28, 5:17AM CDT
The US markets saw a positive sentiment on Tuesday, May 27, 2014, with the NASDAQ Composite closing at 4,237.07, up 1.22%, the Dow Jones Industrial Average ending the session at 16,675.50, up 0.42% and the S&P 500 finishing 0.60% higher at 1,911.91. The gains were broad based as nine out of ten sectors finished on a higher note. A number of stocks saw large movements, including Horizon Pharma Inc. (NASDAQ: HZNP), Celldex Therapeutics Inc. (NASDAQ: CLDX), Extreme Networks Inc. (NASDAQ: EXTR) and WidePoint Corp. (NYSE MKT: WYY). Free technical research on HZNP, CLDX, EXTR and WYY can be downloaded upon signing up at: (full story)
Critical Alerts For Celldex Therapeutics, Best Buy, Weibo, Sarepta Therapeutics, and Dollar Tree Released By InvestorsObserver
PR Newswire - Fri May 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CLDX, BBY, WB, SRPT, and DLTR. (full story)
Shares of CLDX Down 48.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 22, 9:11AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 2 months, Celldex Therapeutics has returned 48.21% as of today's recent price of $12.85. (full story)
Financial Results, Data Presentations, and Breakthrough Therapy Designation - Analyst Notes on Insys, Seattle Genetics, Cubist, Celldex and Clovis
PR Newswire - Thu May 22, 6:10AM CDT
Today, Analysts Review released its analysts' notes regarding Insys Therapeutics, Inc. (NASDAQ: INSY), Seattle Genetics Inc. (NASDAQ: SGEN), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Celldex Therapeutics Inc. (NASDAQ: CLDX) and Clovis Oncology, Inc. (NASDAQ: CLVS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2784-100free. (full story)
Celldex Therapeutics (CLDX) Showing Signs Of A Dead Cat Bounce Today
at The Street - Wed May 21, 9:08AM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate (full story)
Biotech Stock Roundup: Celldex, Incyte Tie Up with Big Pharma for Immuno-Oncology - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 21, 8:22AM CDT
The immuno-oncology field is attracting a lot of interest with a couple of deals being announced last week. (full story)
What Bristol and Celldex's Team-Up Means for Investors
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue May 20, 5:30PM CDT
Bristol Myers-Squibb and Celldex agreed to team up in a phase 1/2 study combining nivolumab (Bristol's PD-1 immuno-oncology candidate) and varlilumab. The study will cover several tumor types, potentially including metastatic melanoma,... (full story)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Celldex Therapeutics Is Down 8.9% (CLDX)
Comtex SmarTrend(R) - Mon May 19, 12:50PM CDT
Two weeks ago on May 1st, 2014 Celldex Therapeutics (NASDAQ:CLDX) reported earnings and analysts, on average, expected a loss of $0.27 on sales of $337.0 thousand. The company actually reported a loss of $0.33 per share on sales of $416.0 thousand, missing EPS estimates by $0.06 and matching revenue estimates. Since the company's report, shares of Celldex Therapeutics have fallen from $14.64 to $13.33, representing a loss of 8.9% in the past 18 days. (full story)
(0)
(0)Celldex Therapeutics Inc (CLDX) Stock Research Links
Scroll down for more posts ▼